12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Rilonacept Regeneron rilonacept regulatory update

Regeneron voluntarily withdrew marketing authorization in the EU for Rilonacept Regeneron rilonacept to treat cryopyrin-associated periodic syndromes (CAPS) and said it will discontinue all development of rilonacept. The drug was approved for CAPS in the EU but was never marketed. Regeneron said it withdrew the...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >